The effect of food intake on the pharmacokinetics of sustained-release morphine sulfate capsules

Clinical Therapeutics

Volumn 19, Issue 2, 1997, Pages 296-303

  Kaiko, Robert F ^a  

^a PURDUE PHARMA L P   (United States)

Author keywords

food effects; morphine; pharmacokinetics; sustained release morphine sulfate capsules

Indexed keywords

MORPHINE SULFATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MIXTURE; FOOD INTAKE; HUMAN; HUMAN EXPERIMENT; LIPID DIET; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

EID: 0030927906     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80117-8     Document Type: Article

References (9)

1. World Health Organization. Cancer pain relief and palliative care. Technical Report Series 804. Geneva: World Health Organization; 1990.
2. Jacox A, Carr DB, Pain R, et al. Management of cancer pain. Clinical Practice Guideline No. 9, AHCPR Publication No. 94-0592. Rockville, Md: US Department of Health and Human Services, Agency for Health Care Policy and Research; March 1994.
3. Kaiko RF, Lazarus H, Cronin C, et al. Controlled-release morphine bioavailability (MS Contin® Tablets) in the presence and absence of food. Hospice J. 1990;6: 17-30.
4. Kaiko RF, Grandy R, Thomas G, et al. A single-dose study of the effect of food ingestion and timing of dose administration on the pharmacokinetic profile of Roxanol SR 30 mg (sustained-release morphine sulfate) tablets. Curr Ther Res. 1990;47:869-878.
5. Gourlay GK, Plummer JL, Cherry DA, et al. Influence of a high-fat meal on the absorption of morphine from oral solution. Clin Pharmacol Ther. 1989;46:463-468.
6. US Food and Drug Administration. Guide-lines for oral extended (controlled) release dosage forms in vivo bioequivalence and in vitro dissolution testing. Rockville, Md: Division of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration; September 1993.
7. Maccarrone C, West RJ, Broomhead AF, Hodsman GP. Single dose pharmacokinetics of Kapanol™, a new oral sustained-release morphine formulation. Drug Invest. 1994;7:262-274.
8. Gourlay GK, Cherry DA, Onley MM, et al. Once a day (i.e. 24 hourly) Kapanol™, a new sustained release morphine formulation, in the treatment of cancer pain: Pharmacokinetic aspects. Eur J Cancer. 1995;31(Suppl 5):S187. Abstract 897.
9. Gourlay GK, Plummer JL, Cherry DA, Onley MM. A comparison of Kapanol (a new sustained-release morphine formulation), MST Continus, and morphine solution in cancer patients: Pharmacokinetic aspects of morphine and morphine metabolites. In: Gebhart GF, Hammond DL, Jensen TS, eds. Proceedings of the 7th World Congress on Pain. Progress in Pain Management, Vol. 2. Seattle, Wash: IASP Press; 1994.